A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria

Study Snapshot

• Program: EVO756
• Study ID(s): NCT06603220
• Phase: Phase 2
• Indication: Chronic Inducible Urticaria
• Status: Completed
• Sponsor: Evommune, Inc.

Design

• Study type: INTERVENTIONAL
• Randomization / allocation: NA
• Intervention model: SINGLE_GROUP
• Masking: NONE
• Primary purpose: TREATMENT
• Enrollment: 30 (ACTUAL)

Population

• Conditions: Chronic Inducible Urticaria
• Sex: ALL
• Age range: 18 Years to 65 Years
• Healthy volunteers: False
• Summary: This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism and cold urticaria.

Operational design summary

• Arms represented in current CT.gov export: 1
• Active dose regimens represented in current local source layer: 1
• Total study enrollment in CT.gov: 30 (ACTUAL)
• Per-arm sample size summary: EVO756 n=30
• Arm-size evidence source: ClinicalTrials.gov arm descriptions and summary text.

Arms

Key Efficacy and Safety Findings

• Result status: Conference

Efficacy

• Open-label study in symptomatic dermographism (n = 30, 300 mg QD or 50 mg BID, 4 weeks).
• 93% of patients showed clinical response at 4 weeks in either FricTest score or Pruritus-NRS.
• 70% improved in FricTest score; 30% achieved complete FricTest response.
• 82% had reduced Pruritus-NRS; 41% achieved clinically meaningful >= 4-point itch NRS reduction.
• Onset of improvement as early as week 1 (including 3 complete responses at week 1).
• 50% of complete responders were IgE-high (>= 100 IU/mL), showing activity not limited to IgE-low patients.

Safety

• No serious TEAEs; no discontinuations due to AEs; well tolerated and consistent with Phase 1 profile.

Result source(s)

• raw/sponsors/mrgprx2/evo756/eadv-2025-cindu-presentation-pdf.md
• raw/sponsors/mrgprx2/evo756/cindu-top-line-press-release-pdf.md

Endpoints

• Primary outcomes:
• Safety and tolerability (time frame: Day 1 to Week 6)

Clinical Pharmacology Findings

• PK: Not clearly summarized in the currently linked local source snippets.
• PD: Not clearly summarized in the currently linked local source snippets.
• Linked manuscripts: No trial-level primary publication is explicitly linked in the current registry.

Safety Findings

• Safety detail is not strongly enriched beyond the current CT.gov/source-registry layer.

Linked Evidence

• CT.gov page: https://clinicaltrials.gov/study/NCT06603220
• Local CT.gov cache: raw/clinicaltrials/markdown/NCT06603220.md

Interpretation

• Verified facts: this page reflects the current local registry and CT.gov inventory export without inferring unsupported arm sizes or endpoint results.
• Interpretation: this trial is currently represented mainly by CT.gov and any linked sponsor-source artifacts; manual enrichment is still needed for a richer narrative page.
• Open questions:
• Some studies still lack exact arm-specific N in the current promoted evidence layer even when allocation schema or total enrollment is visible.
• No explicit trial-level primary manuscript is currently linked in the registry.
• No sponsor artifact is explicitly linked to this trial by identifier in the current registry.

Provenance

• Source type: ClinicalTrials.gov inventory with linked sponsor/publication registry where available
• Primary source(s):
• NCT06603220
• ../raw/clinicaltrials/markdown/NCT06603220.md
• ../inventories/source_registry.json
• Supporting source(s):
• ../inventories/ctgov_priority_trials.json
• Last verified: 2026-04-08
• Verification status: Partial

Change Log

• 2026-04-08: Generated or refreshed this study page from the v2 source registry and CT.gov inventory.